GLPwatch
[Potentiation of weight reduction with GLP-1 receptor agonists].
Rev Med Suisse · 2021
Last updated 2026-05-28GLP-1 receptor agonists are diabetes medications that also lead to significant weight loss by reducing appetite through effects on the brain and body. Studies show higher doses of these drugs can increase weight loss, and combining them with another medication (SGLT2 inhibitors) may further help by causing the body to lose calories through urine. A new drug called tirzepatide, which combines two hormones (GLP-1 and GIP), is also being developed to enhance weight reduction.
AI summary of the abstract below.
| Journal | Rev Med Suisse, 2021 |
|---|---|
| Citations | 2 |
| Relative citation ratio | 0.12 |
| NIH percentile | 8 |
| Molecules | — |
| Conditions studied | Obesity |
Abstract
Glucagon-like peptide-1 receptor agonists are the antidiabetic agents that are associated with the greatest weight loss beyond a marked reduction in glycated haemoglobin. Weight loss results from a reduction in appetite through a predominant central effect combined with a peripheral effect. Liraglutide and semaglutide are developed for the treatment of obesity, independently of type 2 diabetes. Three approaches may be considered to potentiate weight loss: an increase of the drug dosage because of the demonstration of a dose-response, an add-on therapy with a sodium-glucose cotransporter type 2 inhibitor as this agent exerts a complementary action through urinary calorie loss (glucosuria) or a combination of the effects of two incretin hormones (GLP-1 and GIP), as the potent dual agonist tirzepatide currently in development.
Verbatim abstract via PubMed 34431633 ↗